Skip to nav Skip to content

COVID-19 AdvisoryVisitors limited to only one parent/caregiver at all clinics and no siblings allowed. Learn more.

IL1RAP CARs and CAR T cells

Novel CARs and CAR T cells targeting IL1RAP expressing cancers

 

Technology overview

Interleukin-1 receptor accessory protein (IL1RAP) is a cell surface molecule that is overexpressed in hematologic malignancies and in certain solid tumors. Notably, IL1RAP is over expressed in acute myeloid leukemia, chronic myeloid leukemia and in pediatric solid tumors including Ewing’s sarcoma. IL1RAP is also expressed in subsets of adult carcinomas including pancreatic cancer, thyroid cancer, endometrial cancer, lung cancer, renal cancer, and liver cancer. Antibody and CAR T-cell-based therapeutics targeting IL1RAP have been validated in preclinical studies and clinical trials in adults are forthcoming.

Dr. Rimas Orentas has developed novel CARs that specifically target IL1RAP. T cells expressing the IL1RAP CARs successfully targeted and lysed Ewing’s sarcoma cell lines in vitro. These CARs are novel compositions of matter that can be incorporated into other therapeutic immune effector cells including NK cells.

Applications

  • CAR T-cell therapy for IL1RAP-expressing cancers
  • CAR T-cell therapy for solid tumors
  • IL1RAP CAR can be used with different immune effector cells

Advantages

  • Novel IL1RAP specific CAR

Market overview

The global CAR T-cell therapy market was valued at USD $467 million in 2018 and is expected to reach USD $2.9 billion by 2023, growing at a CAGR of 44.1%. Ewing’s sarcoma is the second most common primary bone tumor in children and accounts for approximately 2% of all childhood cancer diagnoses. Acute myeloid leukemia is one of the most common types of leukemia in adults, and chronic myeloid leukemia accounts for 15% of all new cases of leukemia.

Availability

Exclusive license

Technology type

Therapeutic

Cell therapy

Technology status

Preclinical in vitro

Patent status

Patent pending

Developers

Rimas Orentas, PhD

Learn more

To learn more about this technology, please email Kamya Rajaram.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies